Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014

Description:

DelveInsights, Fatty Liver Disease-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fatty Liver Disease. – PowerPoint PPT presentation

Number of Views:42
Slides: 15
Provided by: addyparker2350

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014


1
Fatty Liver Disease-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/77058/-fatty-l
    iver-disease-pipeline-insights-2014

2
Summary
  • DelveInsights, Fatty Liver Disease-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication. A key objective of the report is to
    establish the understanding for all the pipeline
    drugs that fall under Fatty Liver Disease. This
    report provides information on the therapeutic
    development based on the Fatty Liver Disease
    dealing with all the pipeline drugs, comparative
    analysis at various stages covering Filed, Phase
    III, Phase II, Phase I, IND filed, Preclinical,
    Discovery and unknown stages, therapeutics
    assessment by monotherapy and combination
    products and molecule type drug information. The
    report also covers the companies information
    involved in the therapeutic development of the
    products. It also has highlighted the
    discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Note This report requires
    certain updates. We have all the information
    available but require 3 business days to complete
    the process and ensure it is as up-to-date as
    possible. Certain sections in the report may be
    removed or altered based on the availability and
    relevance of data for the indicated Indication.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Fatty Liver DiseaseThe
    report provides pipeline products under drug
    profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the Fatty Liver Disease
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    typeThe report reviews key players involved in
    the therapeutics development for Fatty Liver
    Disease and also provide company profilingThe
    report also gives the information of dormant and
    discontinued pipeline projects Pipeline products
    coverage based on various stages of development
    ranging from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete Pipeline intelligence
    and complete understanding over therapeutics
    development for Fatty Liver DiseaseIdentify the
    relationship between the drugs and use it for
    target finding, drug repurposing, and precision
    medicine.Devise corrective measures for pipeline
    projects by understanding Fatty Liver Disease
    pipeline depth and focus of Indication
    therapeutics Developing strategic initiatives to
    support your drug development activities.Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and ScopeProvides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipelineGaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

7
Table of Content
  • Fatty Liver Disease OverviewFatty Liver Disease
    Pipeline TherapeuticsFatty Liver Disease
    Therapeutics under Development by
    Companies Fatty Liver Disease Late Stage
    Products (Filed and Phase III)Comparative
    Analysis Fatty Liver Disease Mid Clinical Stage
    Products (Phase II)Comparative Analysis Fatty
    Liver Disease Early Clinical Stage Products
    (Phase I and IND Filed)Comparative
    Analysis Fatty Liver Disease Discovery and
    Pre-Clinical Stage Products Comparative
    Analysis Drug Candidate Profiles

8
Table of Content
  • Fatty Liver Disease Therapeutics
    Assessment Assessment by Monotherapy
    Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type Fatty Liver Disease Discontinued
    Products Fatty Liver Disease Dormant
    ProductsCompanies Involved in Therapeutics
    Development for Fatty Liver Disease Appendix Met
    hodology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for Fatty
    Liver Disease, 2014Number of Products under
    Development by Companies Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014Drug Candidates Profiles

10
List of Tables
  • Fatty Liver Disease Assessment by Monotherapy
    Products Fatty Liver Disease Assessment by
    Combination Products Fatty Liver Disease
    Assessment by Route of Administration Fatty
    Liver Disease Assessment by Stage and Route of
    Administration Fatty Liver Disease Assessment by
    Molecule Type Fatty Liver Disease Assessment by
    Stage and Molecule Type Fatty Liver Disease
    Therapeutics Discontinued Products Fatty Liver
    Disease Therapeutics Dormant ProductsProducts
    under Development by Companies, 2014

11
List of Figures
  • Number of Products under Development for Fatty
    Liver Disease, 2014Late Clinical Stage Products
    (Filed and Phase III), 2014Mid Clinical Stage
    Products (Phase II), 2014Early Clinical Stage
    Products (Phase I and IND Filed), 2014Discovery
    and Pre-Clinical Stage Products, 2014Fatty Liver
    Disease Assessment by Monotherapy Products Fatty
    Liver Disease Assessment by Combination
    Products Fatty Liver Disease Assessment by Route
    of Administration Fatty Liver Disease Assessment
    by Stage and Route of Administration Fatty Liver
    Disease Assessment by Molecule Type Fatty Liver
    Disease Assessment by Stage and Molecule Type

12
Related Reports
  • The Mobile Healthcare (mHealth) Bible 2014 -
    2020
  • Pregnancy Detection Kit Market in the US
    2015-2019
  • Global Prenatal and Newborn Genetic Testing
    Market 2015-2019
  • Global Knee Implant market 2015-2019
  • Global Isosorbide Market 2015-2019
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Fatty Liver Disease-Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights, Fatty Liver Disease-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    indication.
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com